The combination of Opsumit (macitentan) and Adcirca (tadalafil) is a safe and effective initial treatment for pulmonary…
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has accepted for review the  application for Tyvaso (inhaled treprostinil) as a…
High pulmonary vascular resistance (PVR) is associated with worse mortality rates among people with pulmonary hypertension (PH), and the bottom…
People with pulmonary arterial hypertension (PAH) who are treated at specialty care centers have better survival chances and a…
U.S. veterans with pulmonary hypertension (PH) due to left heart disease and chronic lung disease are more likely to…
At-home treatment with inhaled nitric oxide through Genosyl, a tankless delivery system, was used successfully to manage pulmonary…
LIQ861, Liquidia Technology‘s investigational inhaled formulation of treprostinil, is safe and well-tolerated in…
The Pulmonary Hypertension Association (PHA) will be participating in a fundraiser for World PH Day on May 5.
Reata Pharmaceuticals is stopping clinical trials evaluating bardoxolone methyl in people with pulmonary arterial hypertension (PAH), including…
The first person with coronavirus disease 2019 (COVID-19) complicating pulmonary hypertension (PH) has received at-home treatment with inhaled…
Treatment with Orenitram (oral treprostinil) is associated with lower healthcare-related costs than treatment with Uptravi (selexipag) in people…
Among people with chronic thromboembolic pulmonary hypertension (CTEPH), certain anticoagulants may reduce the risk of serious bleeding more than…